Chattem

United States Updated 9 July 2026

Chattem is a finished-dose manufacturer based in United States. It appears in 13 regulatory filings across 3 regulators, without an active US DMF or CEP on file. Its filings concentrate with US FDA, ARCSA (EC) and MPA (SE). Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 22 August 2025 as VAI.

active US DMFs

valid CEPs

registered plants 1 with an FDA FEI number

filings across 3 regulators

These figures were checked against the regulators' own files on 25 July 2026

Plants

1 of 1 confirmed

Inspections

7 of 7 confirmed

Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

22 August 2025 VAI US FDA
13 March 2020 VAI US FDA
4 May 2017 NAI US FDA
2 March 2017 NAI US FDA
14 March 2014 NAI US FDA
24 February 2012 NAI US FDA
29 July 2009 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site	FDA FEI
Chattanooga, United States	1022556

Filings and GMP by regulator

Regulator	Filings	GMP certificates
US FDA	10	1
ARCSA (EC)	2	None
MPA (SE)	1	None

Comparing suppliers?

Choose your molecules and target markets. Chattem comes back tiered against every other supplier able to file there.

Start for free

No sales call.

Open risk flags

The most recent inspection outcome was VAI, on 22 August 2025.

Sources on this page

FDA: Drug master files, establishment registration, inspection classifications
EDQM: Certificates of suitability
EudraGMDP and national regulators: GMP certificates